beauti
microarray
analysi
gene
express
mage
use
discov
gene
previous
thought
unrel
physiolog
patholog
event
period
applic
mage
cancer
investig
shift
molecular
profil
identifi
previous
undiscov
cancer
type
predict
outcom
cancer
patient
reveal
metastasi
signatur
solid
tumor
guid
use
therapeut
role
cancer
genom
signatur
evolv
three
phase
first
phase
genom
signatur
describ
store
cancer
specimen
dub
molecular
portrait
cancer
gene
express
profil
care
correl
suffici
clinic
inform
cancer
patient
new
subgroup
cancer
distinct
outcom
reveal
studi
second
phase
valid
cancer
signatur
emphas
commonli
perform
independ
group
cancer
specimen
independ
data
set
third
phase
cancer
genom
signatur
expand
beyond
depict
molecular
portrait
cancer
predict
patient
outcom
guid
use
cancer
therapeut
cancer
genom
signatur
becom
essenti
part
new
gener
cancer
clinic
trial
advoc
futur
clinic
trial
cancer
therapi
cancer
specimen
particip
test
current
avail
predictor
genom
signatur
effect
treatment
least
advers
effect
patient
identifi
particip
triag
appropri
studi
group
taiwan
j
obstet
gynecol
dna
microarray
orderli
arrang
dna
solid
support
provid
medium
match
known
unknown
dna
sampl
type
dna
microarray
relev
methodolog
review
chao
et
al
articl
briefli
review
current
advanc
microarray
analysi
gene
express
mage
focus
recent
report
microarray
qualiti
control
maqc
project
shift
mage
usag
molecular
cancer
profil
clinic
cancer
therapeut
gene
express
profil
gener
continu
gener
extens
inform
molecular
mechan
cellular
function
particular
tissu
physiolog
patholog
event
microarray
analysi
technolog
high
throughput
platform
gene
express
profil
beauti
mage
usual
discov
gene
previous
link
certain
physiolog
patholog
event
instanc
gain
insight
host
respons
sar
infect
tumor
biolog
variou
cervic
cancer
type
molecular
mechan
paclitaxel
treatment
ovarian
cancer
intrins
differ
among
mesenchym
stem
cell
deriv
distinct
origin
dna
microarray
use
analyz
similar
tissu
gene
express
profil
obtain
differ
studi
use
notori
vari
sometim
even
conflict
possibl
caus
discrep
includ
differ
assay
platform
use
differ
sequenc
repres
particular
gene
nonuniform
coverag
gene
set
distinct
data
filter
strategi
variou
statist
stringenc
well
data
complex
variabl
identif
differenti
express
gene
studi
condit
dna
microarray
analysi
often
determin
criteria
set
investig
therefor
concern
rais
regard
reliabl
microarray
result
due
vari
often
conflict
report
address
concern
collabor
effort
led
unit
state
food
drug
administr
includ
scientist
organ
repres
academia
industri
us
govern
complet
maqc
project
project
ident
specimen
aliquot
assign
particip
laboratori
analyz
use
differ
microarray
platform
includ
manufactur
appli
biosystem
affymetrix
agil
ge
healthcar
valid
quantit
capabl
microarray
microarray
result
compar
realtim
quantit
polymeras
chain
reaction
pcr
correl
affymetrix
gene
express
result
taqman
realtim
quantit
pcr
result
shown
good
linear
r
foldchang
rank
method
pvalu
cutoff
recent
shown
reproduc
select
signatur
gene
list
result
use
differ
microarray
platform
select
criteria
shown
reproduc
ttest
p
valu
signific
analysi
microarray
appli
method
select
signatur
gene
express
profil
eas
filter
use
p
rank
gene
fold
chang
chose
top
gene
upregul
group
mesenchym
stem
cell
deriv
amniot
fluid
amniot
membran
cord
blood
adult
bone
marrow
collect
remark
improv
microarray
technolog
aforement
critic
evalu
major
microarray
research
recogn
reliabl
consist
welldesign
care
conduct
microarray
result
even
year
public
maqc
project
clinic
biolog
find
deriv
microarray
regard
remark
robust
high
level
quantit
precis
recent
maqc
result
demonstr
microarray
gene
express
analysi
suitabl
standalon
quantit
comparison
nevertheless
ignor
potenti
flaw
encourag
result
maqc
project
establish
microarray
technolog
robust
impli
technolog
foolproof
quot
commentari
novemb
issu
cell
learn
pcr
well
month
microarray
take
year
evalu
mage
help
make
diagnosi
choos
therapi
research
use
one
set
patient
identifi
geneexpress
pattern
call
genet
signatur
correspond
clinic
issu
surviv
rate
respons
treatment
induct
side
effect
drug
power
microarray
technolog
abil
use
chang
multipl
gene
pattern
gene
express
rather
choos
threshold
individu
marker
genet
signatur
valid
group
patient
trial
period
critic
investig
understand
minim
express
nois
bia
effect
design
express
nois
defin
gene
express
variat
correl
biolog
behavior
studi
introduc
technolog
andor
tissu
process
bia
inher
microarray
analysi
easili
introduc
faulti
experiment
design
seri
sophist
analyt
strategi
address
problem
discuss
summar
tabl
unsupervis
analysi
use
priori
class
definit
simpli
seek
determin
structur
inher
data
commonli
use
exampl
unsupervis
analysi
hierarch
cluster
ie
let
data
defin
pattern
cluster
gene
similar
express
profil
supervis
analysi
like
reveal
put
associ
gene
cytogenet
class
may
bia
outcom
forc
model
onto
data
ie
overfit
risk
extract
robust
profil
multipl
data
set
metaanalysi
done
independ
data
set
deriv
array
experi
identifi
cancer
signatur
activ
cancer
rel
normal
tissu
cancer
aris
metaanalysi
signatur
identifi
gene
activ
signatur
suggest
common
transcript
program
pervad
type
cancer
function
enrich
analysi
seri
extern
function
inform
use
interpret
summar
larg
cancer
signatur
mileston
databas
extern
function
inform
includ
gene
ontolog
wwwgeneontologyorg
kyoto
encyclopedia
gene
genom
wwwgenomejp
kegg
biocarta
wwwbiocartacom
genmapp
wwwgenmapporg
commerci
maintain
integr
databas
softwar
includ
metacor
genego
wwwgenegocommetacorephp
ingenu
system
wwwingenuitycom
recent
use
metacor
suit
analyz
signatur
profil
mesenchym
stem
cell
variou
origin
obtain
insight
biolog
process
group
goal
transcript
network
analysi
simplifi
complex
cancer
signatur
small
number
activ
transcript
program
may
shed
light
neoplast
mechan
point
potenti
target
therapeut
intervent
addit
aforement
function
enrich
analysi
mani
downstream
effector
transcript
factor
chromatin
immunoprecipit
coupl
promot
microarray
chipchip
assay
allow
genomewid
identif
transcript
factorbind
site
hundr
consensu
bind
sequenc
transcript
factor
defin
sequencebas
method
feasibl
perform
largescal
integr
analysi
bindingsit
profil
cancer
signatur
express
profil
analysi
express
modul
function
pathway
ie
gene
modul
use
gene
modul
propos
extend
investig
cancer
gene
express
individu
gene
biolog
process
concept
higherlevel
modul
appli
examin
joint
behavior
differenti
express
gene
diabet
muscl
signific
chang
whole
set
gene
note
even
though
express
individu
gene
significantli
differ
segal
et
al
use
modulelevel
analysi
obtain
global
view
share
uniqu
molecul
modul
underli
human
cancer
demonstr
activ
repress
modul
eg
cell
cycl
share
across
multipl
tumor
type
could
regard
gener
tumorigenesi
wherea
other
eg
growthregulatori
modul
specif
tissu
origin
progress
particular
tumor
applic
mage
clinic
cancer
investig
shift
molecular
profil
year
identifi
previous
undiscov
subgroup
particular
type
cancer
predict
outcom
cancer
patient
reveal
metastasi
signatur
solid
tumor
guid
use
therapeut
summar
tabl
use
mage
guid
cancer
therapeut
also
compar
metaanalys
larg
bcell
lymphoma
leukemia
data
set
bone
marrow
sampl
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
golub
et
al
test
whether
gene
express
monitor
dna
microarray
could
assign
tumor
known
class
class
predict
use
supervis
learn
classif
algorithm
golub
et
al
first
construct
class
predictor
evalu
use
crossvalid
collect
specimen
known
outcom
result
suggest
gener
strategi
discov
predict
cancer
class
prove
use
predict
outcom
patient
tumor
type
proof
principl
perou
et
al
use
cdna
microarray
identifi
gene
differenti
express
vitro
cultur
human
mammari
epitheli
cell
breast
tumor
specimen
result
support
feasibl
use
systemat
approach
studi
variat
gene
express
pattern
human
cancer
mean
dissect
classifi
solid
tumor
surgic
specimen
human
breast
tumor
patient
analyz
gene
express
profil
identifi
set
coexpress
gene
variat
mrna
level
could
relat
specif
featur
physiolog
variat
molecular
portrait
cancer
gene
express
profil
thu
propos
diffus
larg
bcell
lymphoma
dlbcl
one
diseas
subgroup
histolog
difficult
interand
intrapathologist
irreproduc
use
hierarch
cluster
mage
profil
dlbcl
specimen
could
divid
two
distinct
group
case
germin
center
blike
dlbcl
case
activ
blike
dlbcl
statist
patient
germin
center
blike
dlbcl
better
overal
surviv
activ
blike
dlbcl
molecular
classif
tumor
base
gene
express
profil
thu
prove
abil
identifi
previous
undetect
clinic
signific
subtyp
cancer
even
stage
diseas
breast
cancer
notori
unpredict
respons
chemotherapi
variabl
overal
outcom
chemotherapi
hormon
therapi
reduc
risk
distant
metastasi
third
howev
lack
accur
patient
triag
strategi
determin
undergo
adjuv
therapi
mani
patient
might
develop
cancer
metastasi
unnecessarili
undergon
adjuv
therapi
develop
patienttailor
therapi
strategi
breast
cancer
va
nt
veer
et
al
use
supervis
classif
analyz
dna
microarray
data
primari
breast
tumor
young
patient
va
nt
veer
et
al
identifi
poor
prognosi
signatur
could
predict
short
time
interv
distant
metastasi
therefor
result
provid
strategi
select
patient
would
benefit
adjuv
therapi
search
molecular
metastasi
signatur
cancer
ramaswami
et
al
compar
gene
express
pattern
primari
tumor
metastas
identifi
gene
express
signatur
distinguish
primari
metastat
adenocarcinoma
howev
author
found
subset
primari
tumor
resembl
metastat
tumor
confirm
find
appli
express
signatur
data
primari
solid
tumor
divers
type
notabl
ramaswami
et
al
analyz
whole
tumor
tissu
includ
surround
stromal
cell
instead
pure
cancer
popul
could
isol
use
laser
captur
microdissect
metastasi
signatur
identifi
studi
two
collagen
gene
one
lamin
gene
upregul
suggest
malign
product
tumorhost
microenviron
two
articl
prognost
use
gene
express
profil
acut
myeloid
leukemia
aml
studi
also
demonstr
abil
microarray
technolog
use
somewhat
imprecis
pattern
gene
express
rather
exact
threshold
individu
marker
current
mani
prestigi
journal
scienc
natur
seri
ask
author
deposit
microarray
data
minim
inform
microarray
experi
miam
compliant
form
one
two
public
repositori
gene
express
omnibu
nation
center
biotechnolog
informat
http
www
ncbinlmnihgovgeo
array
express
european
bioinformat
institut
http
wwwebiacukarrayexpress
prerequisit
public
microarrayderiv
research
articl
therefor
mani
largescal
microarray
data
set
becam
avail
reanalys
research
worldwid
instanc
multipl
import
paper
breast
cancer
gene
express
profil
deriv
comprehens
microarray
data
set
suffici
clinic
inform
use
sever
microarray
data
set
losso
et
al
metaanalysi
dbcl
select
gene
analysi
realtim
quantit
pcr
independ
sampl
lymphoma
patient
six
gene
show
strongest
predict
power
test
gene
two
addit
independ
microarray
data
set
losso
et
al
conclud
measur
express
six
gene
suffici
predict
overal
surviv
dbcl
use
microarray
gene
express
profil
predict
outcom
cancer
patient
valid
aforement
studi
howev
even
group
sampl
analyz
distinct
prognost
profil
deriv
outcom
predict
resolv
paradox
fan
et
al
compar
predict
power
gene
set
group
specimen
appli
five
geneexpressionbas
model
intrins
subtyp
profil
wound
respons
recurr
score
twogen
ratio
perform
kaplanmei
surviv
analys
patient
breast
cancer
fan
et
al
found
four
five
model
test
show
signific
agreement
outcom
predict
individu
patient
except
model
use
twogen
ratio
could
result
reliabl
predict
explan
surpris
concord
among
four
differ
model
predict
breast
cancer
outcom
like
follow
larg
group
gene
behav
differ
relat
biolog
phenotyp
cancer
ultim
patient
outcom
larg
list
gene
four
model
might
use
construct
signatur
profil
use
predict
outcom
dissect
oncogen
pathway
signatur
human
cancer
bild
et
al
use
adenovir
vector
express
variou
oncogen
activ
myc
ra
src
otherwis
quiescent
cell
appli
strategi
abl
specif
isol
subsequ
event
defin
activationderegul
singl
oncogen
pathway
analyz
event
affymetrix
oligonucleotid
microarray
clinic
sampl
lung
breast
ovarian
cancer
bild
et
al
combin
signaturebas
predict
across
sever
pathway
identifi
coordin
pattern
pathway
deregul
distinguish
specif
cancer
tumor
subtyp
use
pathwayspecif
inhibitor
ra
pathway
inhibitor
either
farnesyltransferas
inhibitor
farnesylthiosalicyl
acid
src
pathway
inhibitor
bild
et
al
could
predict
drug
sensit
test
breast
cancer
cell
line
accord
pathway
deregul
summari
predict
pathway
deregul
cancer
cell
also
predict
sensit
therapeut
agent
target
compon
pathway
result
pave
path
use
oncogen
pathway
signatur
guid
use
target
therapeut
enorm
complex
cancer
frequent
inabl
properli
guid
use
avail
therapeut
chemotherapi
solid
tumor
often
result
margin
success
peopl
advanc
solid
tumor
relaps
die
diseas
furthermor
oncologist
alway
face
challeng
match
right
therapeut
regimen
right
individu
balanc
rel
benefit
risk
achiev
best
outcom
goal
use
genom
signatur
guid
use
chemotherapeut
potti
et
al
systemat
extract
gene
express
profil
follow
microarray
data
set
cancer
cell
line
addit
cancer
cell
line
author
previous
report
breast
ovarian
lung
cancer
specimen
newli
analyz
ovarian
cancer
cell
line
advanc
figo
stage
iii
iv
serou
epitheli
ovarian
cancer
potti
et
al
demonstr
pattern
predict
sensit
three
human
solid
cancer
breast
lung
ovari
seven
common
chemotherapeut
drug
paclitaxel
docetaxel
adriamycin
topotecan
cyclophosphamid
etoposid
evalu
individu
signatur
respond
combin
drug
potti
et
al
also
analyz
breast
cancer
patient
breast
neoadjuv
treatment
studi
use
combin
paclitaxel
adriamycin
cyclophosphamid
tfac
predict
respons
base
combin
probabl
sensit
built
individu
chemosensit
predict
yield
statist
signific
distinct
respond
nonrespond
summar
figur
role
cancer
genom
signatur
evolv
three
phase
first
phase
genom
signatur
describ
store
cancer
specimen
dub
molecular
portrait
cancer
gene
express
profil
care
correl
suffici
clinic
inform
cancer
patient
new
subgroup
cancer
distinct
outcom
reveal
studi
second
phase
valid
cancer
signatur
emphas
commonli
done
independ
group
cancer
specimen
independ
data
set
third
phase
cancer
genom
signatur
expand
beyond
depict
molecular
portrait
cancer
predict
patient
outcom
includ
metastasi
becom
rule
third
phase
prognost
genom
signatur
valid
addit
data
set
potti
et
al
demonstr
role
cancer
genom
signatur
guid
use
cancer
therapeut
new
gener
cancer
clinic
trial
propos
cancer
specimen
particip
test
current
avail
predictor
genom
signatur
effect
treatment
least
advers
effect
patient
could
identifi
particip
triag
appropri
studi
group
figur
fact
success
exampl
treat
patient
earlystag
nonsmal
cell
lung
cancer
report
potti
et
al
treat
advancedstag
ovarian
cancer
dressman
et
al
commonli
argu
microarray
result
fact
transcriptom
necessarili
reflect
correspond
proteom
collect
protein
execut
major
cellular
function
inde
mrna
express
coars
surrog
protein
activ
level
mani
gene
howev
mrna
express
use
surrog
document
mani
studi
one
find
strong
signal
differenti
express
typic
reflect
later
protein
level
latter
valid
protein
assay
enzymelink
immunosorb
assay
immunohistochemistri
current
development
pace
genom
technolog
clinic
trend
toward
person
medicin
almost
certain
figur
mani
biomed
research
clinician
predict
microarray
technolog
incorpor
clinic
laboratori
hospit
near
futur
extrapol
result
studi
discuss
articl
use
focus
array
measur
express
gene
signatur
profil
select
diseas
would
help
clinician
predict
patient
respons
drug
triag
patient
chemorespons
versu
chemoresist
group
evalu
panel
risk
three
phase
genom
signatur
cancer
therapi
new
gener
clinic
trial
schema
adapt
herbst
lippman
potti
et
al
factor
may
result
comorbid
patient
achiev
practic
feasibl
microarray
technolog
would
need
address
rang
qualitycontrol
issu
everi
aspect
process
robust
consid
foolproof
predict
within
next
year
microarray
develop
meet
challeng
